Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...
Clinical Trials Arena on MSN14h
MSD to push for approval of HIV combo after Phase III successMSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...
Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback